Companies › Vaderis Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Cardiovascular, Other; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Engasertib | – | Phase 3 | Hereditary Hemorrhagic Telangiectasia; Healthy Participants | Jun 2028 |
| VAD044 | – | Phase 1 | Hereditary Hemorrhagic Telangiectasia (HHT) | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07800429 | Engasertib | Phase 1 | Healthy Participants | Other | Oct 2026 |
| NCT05406362 | VAD044 | Phase 1 | Hereditary Hemorrhagic Telangiectasia (HHT) | Cardiovascular | Jan 2027 |
| NCT07743671 | Engasertib | Phase 3 | Hereditary Hemorrhagic Telangiectasia | Cardiovascular | Jun 2028 |
No annotated target.
–
RHEACELL GmbH & Co. KG Addpharma Cardurion Pharmaceuticals Research Institute of Geroprotective Technologies Aplagon Oy
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.